Corcept Therapeutics
Corcept Therapeutics is dedicated to unlocking the potential of cortisol modulation to revolutionize the treatment of serious diseases. With over 25 years of research, more than 1,000 novel molecules discovered, and more than 30 ongoing studies across various disease areas, the company is a leader in the research and development of cortisol modulators. Their mission is to unlock the potential of cortisol modulation and transform the treatment landscape for conditions such as endocrinology, oncology, metabolism, and neurology.
Industries
Nr. of Employees
large (251-1000)
Patents
Methods for imaging and treatment of somatostatin-receptor positive tumors
US-12290551-B2
View DetailsMethods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
US-12263169-B2
View DetailsFatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
US-12226417-B2
View Details
Methods for imaging and treatment of somatostatin-receptor positive tumors
US-12290551-B2
View DetailsMethods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
US-12263169-B2
View DetailsFatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
US-12226417-B2
View DetailsProducts
Glucocorticoid receptor antagonist approved for hypercortisolism (mifepristone)
A small-molecule glucocorticoid receptor antagonist approved by the U.S. FDA for treatment of hypercortisolism (endogenous Cushing syndrome).
Selective glucocorticoid receptor modulators (clinical-stage candidates)
Clinical-stage selective glucocorticoid receptor modulators under development for multiple cortisol-impacted diseases across endocrinology, oncology, metabolism and neurology.
Glucocorticoid receptor antagonist approved for hypercortisolism (mifepristone)
A small-molecule glucocorticoid receptor antagonist approved by the U.S. FDA for treatment of hypercortisolism (endogenous Cushing syndrome).
Selective glucocorticoid receptor modulators (clinical-stage candidates)
Clinical-stage selective glucocorticoid receptor modulators under development for multiple cortisol-impacted diseases across endocrinology, oncology, metabolism and neurology.
Services
Design and conduct of clinical trials across Phases 1–4, including randomized, placebo-controlled and combination-therapy studies.
Synthesis and preclinical evaluation of novel small-molecule receptor modulators, including optimization for pharmacokinetics and reduced hERG liability and in vivo efficacy testing.
Analytical and clinical studies to measure drug exposures and assess interactions with other medications, including P-gp substrate evaluations.
Analysis and reporting of treatment-emergent adverse events from clinical trials to evaluate tolerability and safety profiles.
Partnership support and facilitation for externally led clinical research projects in cortisol-impacted diseases.
Design and conduct of clinical trials across Phases 1–4, including randomized, placebo-controlled and combination-therapy studies.
Synthesis and preclinical evaluation of novel small-molecule receptor modulators, including optimization for pharmacokinetics and reduced hERG liability and in vivo efficacy testing.
Analytical and clinical studies to measure drug exposures and assess interactions with other medications, including P-gp substrate evaluations.
Analysis and reporting of treatment-emergent adverse events from clinical trials to evaluate tolerability and safety profiles.
Partnership support and facilitation for externally led clinical research projects in cortisol-impacted diseases.
Expertise Areas
- Glucocorticoid receptor drug discovery
- Clinical trial management (Phases I–IV)
- Medicinal chemistry and lead optimization
- Preclinical in vivo pharmacology
Key Technologies
- Glucocorticoid receptor modulation
- Selective small-molecule receptor modulators
- Synthetic organic medicinal chemistry
- In vivo rodent disease models
News & Updates
A Phase 4 study assessing hypercortisolism in patients with difficult-to-control type 2 diabetes despite standard-of-care therapies.
Relacorilant was well tolerated in patients with endogenous hypercortisolism and demonstrated an acceptable and consistent safety profile.
A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
A Phase 4 study assessing hypercortisolism in patients with difficult-to-control type 2 diabetes despite standard-of-care therapies.
Relacorilant was well tolerated in patients with endogenous hypercortisolism and demonstrated an acceptable and consistent safety profile.
A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.